Angiolutions announces advisory board to accelerate early-stage treatment for abdominal aortic aneurysms

Composed of leading experts from medicine, research & industry

Aims to accelerate the clinical testing and market launch of Angiolutions’ early aneurysm treatment

Share this on:

July 3, 2024 – Angiolutions announces its Advisory Board, comprising industry leaders, distinguished researchers, and clinicians from world-renowned institutions. Each member brings unique expertise to advance Angiolutions’ mission of delivering the first implant designed to stop abdominal aortic aneurysms at an early stage to patients.

Meet the Angiolutions Advisory Board!

Ruti Alon

Board Member,
Business Advisor

Set up the life science unit at Pitango, Israel’s largest tech VC with exits worth approximately $1.4 billion.

Prof. Dr. med.
Lars Maegdefessel

Board Member,
Science Advisor
Director, Institute of Molecular Vascular Medicine at Technical University of Munich.

Eileen Rose

Board Member,
Industry Advisor
Formerly led the interventional cardiology clinical studies unit at Boston Scientific.

Prof. Dr. med.
Hubert Schelzig

Board Member,
Clinical Advisor
One of Germany’s most prominent vascular clinicians, Head of Vascular Surgery Department, University Hospital Düsseldorf.

Dr. Hannah Teichmann

Board Member,
Innovation Advisor

Successfully scaled her medical device startup MMI to over 100 people.

Prof. Philip S. Tsao

Board Member,
Science Advisor
Professor for Cardiovascular Medicine at Stanford University School of Medicine and international key opinion leader in aneurysm research.

"Our experienced and diverse board constantly challenges and inspires us. This helps us to accelerate our efforts to bring the first implant to stop early-stage abdominal aortic aneurysms to market."

stated Dr. Isabel N. Schellinger, Angiolutions’ CEO and Co-founder.
Angiolutions Advisory Board Members at a recent meeting in Germany
Members of the Angiolutions Board and the Angiolutions leadership team at a recent board meeting in Germany

About Angiolutions

Angiolutions revolutionizes the treatment of life-threatening abdominal aortic aneurysms (AAAs) with a first-of-its-kind medical device that stops AAA growth at an early stage. AAA is a progressive dilation of the biggest blood vessel of our body affecting 1 in 20 people. By treating early-stage AAA, Angiolutions brings new hope to hundreds of thousands of patients that are currently without a treatment option. 



Please leave your message here